


INFECTED BLOOD INQUIRY

BRENDON GRAY WITNESS STATEMENT

EXHIBIT WITN6984124

Bayer



Memorandum

Pharmaceutical Business Group -----

From Phil Blake

Date 5 April 1993

To M French
A Arter
N Edwards

Ref PB/rmc
M05.13

SUBJECT: KOATE HP

As you are aware we are very keen to register and sell this product in the UK.

Launching Koate HP in the UK before the end of 1994 will have the following advantages:-

- 1) Presence in the market before the launch of Kogenate
- 2) A bargaining counter when selling Kogenate
- 3) Sales revenue; since at the USA price of 22c we can undercut the BPL national product (30c) and sell significant quantities

Unfortunately, there seems to be a problem in registering Koate HP in our country. The problem appears to revolve around the production limits being different from the FDA registration limits.

Please inform me if we have any chance of registering this product. Our registration group is asking similar questions of Miles BP (Eli Green).

We need to have a realistic estimate of Koate HP's chances to enable us to plan a successful introduction of Kogenate.

Kind regards

GRO-C

Phil Blake